Bioventures 2014 L.P. Mpm Sells 41,152 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 41,152 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $0.89, for a total value of $36,625.28. Following the transaction, the insider owned 5,321,436 shares in the company, valued at $4,736,078.04. This represents a 0.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $62,344.56.
• On Tuesday, November 18th, Bioventures 2014 L.P. Mpm sold 52,627 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $48,943.11.
• On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.95, for a total transaction of $54,207.95.
• On Friday, November 14th, Bioventures 2014 L.P. Mpm sold 61,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total transaction of $57,325.20.
• On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $89,131.98.
• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $63,623.40.
• On Monday, November 10th, Bioventures 2014 L.P. Mpm sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total value of $57,312.60.
• On Friday, November 7th, Bioventures 2014 L.P. Mpm sold 68,480 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $76,012.80.
• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total value of $65,886.92.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock traded down $0.07 during midday trading on Thursday, reaching $0.85. The company’s stock had a trading volume of 465,207 shares, compared to its average volume of 732,451. The firm has a market capitalization of $41.49 million, a PE ratio of -0.53 and a beta of 0.72. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $2.38. The stock’s 50 day simple moving average is $1.55 and its 200 day simple moving average is $1.33. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. On average, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its position in Werewolf Therapeutics by 33.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after acquiring an additional 23,852 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Werewolf Therapeutics in the first quarter valued at $71,000. MPM Asset Management LLC increased its stake in Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the last quarter. MPM Bioimpact LLC increased its stake in Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in Werewolf Therapeutics during the first quarter worth about $79,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on HOWL. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. JMP Securities reduced their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Finally, Bank of America lowered their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.